MedTherapy has reduced the manufacturing timeline for CAR-T gene therapy from several months to one day [1].
This acceleration in production could dismantle significant financial and temporal barriers to life-saving cancer treatments. By slashing the time and cost associated with personalized gene therapy, India may position itself as a primary global destination for affordable oncology care.
Dr. Bikesh Verma, CEO of MedTherapy, said the company has cut the costs of these therapies by nearly 70% [2]. This reduction is driven by technological advancements that streamline the complex process of modifying a patient's own T-cells to fight cancer.
MedTherapy is currently preparing to launch a product specifically targeting blood cancer. The release of this treatment is pending government approval in India [1].
Verma said the objective is to transform India into a hub for affordable cancer gene therapies. The shift from a multi-month process to a 24-hour window represents a fundamental change in how these biological drugs are delivered to patients [1].
CAR-T therapy traditionally requires extracting blood from a patient, genetically engineering the cells in a laboratory, and then reinfusing them. This cycle often takes weeks or months, during which time a patient's health can deteriorate. The new process aims to eliminate that waiting period [1].
While the company awaits regulatory clearance, the reported cost efficiency suggests a move toward democratizing high-end biotechnology. The integration of faster manufacturing and lower price points could allow more patients to access treatments that were previously reserved for the wealthiest populations [2].
“MedTherapy has reduced the manufacturing timeline for CAR-T gene therapy from several months to one day.”
The transition of CAR-T manufacturing from a months-long process to a single day suggests a shift toward 'point-of-care' manufacturing. If validated by regulators, this would move gene therapy from a rare, boutique medical procedure to a scalable industrial process, potentially lowering the global price floor for cancer treatment and increasing patient survival rates by reducing the window of disease progression during production.
